V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20039587 | 20086114 | 1.6 | 65 | Palliative (P) | 2019-02-25 | 2019-03-07 | R GCVP | 02 | N | ABC-08 TRIAL | 100986082 |
| 20039610 | 20086115 | 1.63 | 52.6 | Palliative (P) | 2017-09-14 | 2017-09-30 | Cladribine (subcut) 5 days | 02 | Y | CHLORAMBUCIL + RITUXIMAB | 100180644 |
| 20039611 | 20086116 | 1.73 | 60.5 | Palliative (P) | 2018-07-27 | 2018-08-20 | Lenalidomide 25mg (Cycle 1 to 25) | 02 | N | CAV | 101599059 |
| 20039613 | 20086117 | 1.79 | 80 | 03 | null | 2018-08-14 | Panitumumab | 2 | N | DARATUMUMAB | 101844247 |
| 20039631 | 20086118 | 1.6 | 56 | Adjuvant (A) | null | 2018-09-14 | null | 01 | N | EPIRUBICIN + FLUOROURACIL + OXALIPLATIN | 101592259 |
| 20039664 | 20086119 | null | null | Adjuvant (A) | 2017-04-30 | 2017-05-14 | Docetaxel | null | N | RITUXIMAB | 100217147 |
| 20039667 | 20086120 | 1.59 | 83.6 | Adjuvant (A) | 2018-02-15 | 2018-02-16 | CARBOPLATIN + FLUOROURACIL | 02 | N | CAPECITABINE + LOMUSTINE | 100651558 |
| 20039677 | 20086122 | 1.73 | 68 | 03 | null | 2017-10-30 | Rituximab | 2 | N | PANITUMUMAB | 101489669 |
| 20039774 | 20086123 | 1.68 | 43.1 | null | 2017-05-03 | 2017-05-30 | CAP + RT | 02 | N | FOXTROT TRIAL | 101212461 |
| 20039805 | 20086124 | 1.77 | 77.5 | 03 | 2018-04-03 | 2018-04-08 | NIVOLUMAB | 02 | N | CAPECITABINE + CETUXIMAB + OXALIPLATIN | 100410436 |
| 20039834 | 20086125 | 1.72 | 107.6 | Palliative (P) | 2016-11-17 | 2016-11-17 | FEC + DOCETAXEL | N | Y | FOXFIRE TRIAL | 101539079 |
| 20039900 | 20086126 | 1.67 | 0 | null | 2018-08-01 | 2018-08-01 | MITOMYCIN | 02 | N | EPIRUBICIN + FLUOROURACIL + OXALIPLATIN | 101339465 |
| 20039973 | 20086129 | 1.69 | 90.6 | null | 2016-11-11 | 2016-12-01 | Cisplatin+Fluorouracil+Streptozoc | 02 | N | BORTEZOMIB + PANOBINOSTAT | 100164103 |
| 20039977 | 20086130 | 1.74 | 94.5 | 03 | 2016-11-04 | 2016-12-02 | PEMBROLIZUMAB | 02 | Y | SCOPE 1 TRIAL | 100786871 |
| 20039986 | 20086131 | 1.79 | 51 | Adjuvant (A) | 2019-10-26 | 2019-11-24 | Chlorambucil | N | N | MIC | 100683547 |
| 20040043 | 20086132 | null | null | Adjuvant (A) | 2018-10-31 | 2018-11-01 | CARBOPLATIN + DOXORUBICIN + MITOMYCIN | N | N | NAB-PACLITAXEL | 101022764 |
| 20040110 | 20086133 | 1.65 | 58.3 | Palliative (P) | 2019-02-06 | 2019-02-18 | Gemcitabine + Paclitaxel | 02 | N | DOXORUBICIN | 101345683 |
| 20040145 | 20086134 | 1.5 | 98.9 | Not known (9) | 2018-09-27 | 2018-10-04 | Cisplatin +FU +Trastuzumab - Load | 02 | Y | NOT MATCHED | 101307644 |
| 20040147 | 20086135 | 1.59 | 80 | 03 | null | 2019-06-05 | CHOP R - 21 days | N | N | PRIMUS 002 TRIAL | 100399449 |
| 20040165 | 20086136 | 1.7 | 54 | Palliative (P) | null | 2018-01-12 | Docetaxel 75mg/m2 (21 day) | 2 | N | TEYSUNO | 100210046 |
| 20040265 | 20086137 | 1.72 | null | Palliative (P) | 2017-09-09 | 2017-09-16 | PEMBROLIZUMAB | 02 | N | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 101718806 |
| 20040290 | 20086138 | 1.8 | 76 | null | 2016-11-11 | 2016-11-11 | Rituximab | 02 | N | HYDROXYCARBAMIDE | 101537334 |
| 20040360 | 20086140 | 1.82 | 78 | 03 | 2018-10-29 | 2018-11-27 | CHOEP | 02 | null | MITOMYCIN | 100625665 |
| 20040390 | 20086141 | 1.81 | 112 | Palliative (P) | 2017-11-06 | 2017-11-16 | VDC | 99 | N | OXALIPLATIN + MDG + PANITUMUMAB | 100153012 |
| 20040441 | 20086142 | 1.75 | 70.9 | Neo-adjuvant (N) | 2017-10-19 | 2017-11-17 | Fluorouracil + Folinic + RT Bossett | N | N | NOT MATCHED | 100976006 |
| 20040527 | 20086144 | null | null | Curative (C) | 2017-10-31 | 2017-11-27 | CAPECITABINE + OXALIPLATIN + RT | 01 | null | DABRAFENIB + TRAMETINIB | 101120597 |
| 20040564 | 20086145 | 1.6 | 62 | 03 | null | 2018-03-19 | MELPHALAN + THALIDOMIDE | 99 | null | BORTEZOMIB + CYCLOPHOSPHAMIDE | 100304875 |
| 20040598 | 20086146 | 1.52 | 73.8 | 03 | 2019-08-09 | 2019-08-15 | Carboplatin+Fluorouracil 4 or 5 day | 02 | N | HYDROXYCARBAMIDE | 100416866 |
| 20040608 | 20086147 | 1.62 | 69.4 | 03 | 2017-01-12 | 2017-02-14 | TEMOZOLOMIDE | N | Y | IRINOTECAN | 101336625 |
| 20040611 | 20086148 | 1.52 | 79.3 | Palliative (P) | 2021-07-14 | 2021-07-16 | Capital Trial | 01 | N | PANITUMUMAB | 101505343 |
| 20040612 | 20086149 | 1.82 | 69.95 | null | 2016-07-27 | 2016-07-30 | Cisplatin + Vinorelbine (PO) | 02 | N | PLATO TRIAL | 101227502 |
| 20040656 | 20086150 | 1.5 | 76 | 03 | 2019-09-14 | 2019-09-16 | Hepatoblastoma SR Cisplatin | 02 | N | CARBO + FLUOROURACIL | 101661611 |
| 20040659 | 20086151 | 1.63 | 89.7 | Palliative (P) | 2018-03-04 | 2018-03-09 | ACTICCA-1 Trial | 02 | N | ACTICCA-1 TRIAL | 101027326 |
| 20040675 | 20086152 | null | null | Palliative (P) | 2015-06-07 | 2015-06-19 | GO2 TRIAL | N | N | EVEROLIMUS | 101180233 |
| 20040752 | 20086153 | 1.87 | 56.4 | Adjuvant (A) | 2018-02-15 | 2018-02-15 | Everolimus 10mg | 02 | N | MPV | 100828184 |
| 20040760 | 20086154 | 1.51 | 78.4 | Palliative (P) | 2016-10-27 | 2016-11-21 | CAPECITABINE + CARBOPLATIN + Trastuzumab | 02 | N | IBRUTINIB | 100248847 |
| 20040761 | 20086155 | null | null | Adjuvant (A) | 2019-06-03 | 2019-06-04 | CAP + RT | 02 | N | ACTICCA-1 TRIAL | 101420220 |
| 20040763 | 20086156 | 1.78 | 87.6 | Palliative (P) | 2016-08-10 | 2016-08-10 | Abiraterone | 02 | N | PANITUMUMAB | 101543411 |
| 20040828 | 20086157 | null | 102.1 | Palliative (P) | 2016-06-10 | 2016-07-14 | CISPLATIN + TEYSUNO | 02 | N | CARBOPLATIN + DOCETAXEL + TRASTUZUMAB | 100294109 |
| 20040914 | 20086159 | 1.82 | 56 | Palliative (P) | 2016-10-30 | 2016-11-06 | CISPLATIN + FLUOROURACIL + Trastuzumab | N | N | CHLORAMBUCIL | 100760205 |
| 20040930 | 20086160 | 1.77 | 50.7 | null | 2018-07-13 | 2018-07-22 | null | 02 | N | NEO-AEGIS TRIAL | 101096229 |
| 20040938 | 20086161 | 1.73 | 60.5 | Palliative (P) | 2019-04-06 | 2019-04-07 | MITOMYCIN | 01 | N | SCOPE2 TRIAL | 100966600 |
| 20041002 | 20086164 | null | null | Palliative (P) | 2018-02-28 | 2018-03-12 | CAP + RT | 02 | null | CHLORAMBUCIL + OBINUTUZUMAB | 100600973 |
| 20041049 | 20086165 | 1.8 | 11.9 | 03 | 2017-02-25 | 2017-03-11 | null | 02 | N | RALTITREXED | 100350537 |
| 20041066 | 20086166 | 1.6 | 56 | 03 | 2018-08-06 | 2018-08-08 | FEC | null | N | RITUXIMAB | 101154721 |
| 20041170 | 20086169 | 1.74 | 105 | null | 2018-06-11 | 2018-06-24 | NEO-AEGIS TRIAL | 02 | N | BORTEZOMIB | 100409802 |
| 20041188 | 20086170 | 1.5 | 49 | 03 | 2019-12-03 | 2019-12-10 | LIPOSOMAL DAUNORUBICIN + CYTARABINE (Vyxeos) | 02 | N | CAP + RT | 101539650 |
| 20041197 | 20086171 | 1.52 | 120.2 | Adjuvant (A) | 2018-08-14 | 2018-08-25 | Cisplatin + Docetaxel +Fluorouracil | 02 | N | DOCETAXEL | 100402190 |
| 20041220 | 20086172 | 1.66 | 61.8 | null | 2018-10-04 | 2018-10-08 | Cisplatin+Fluorouracil+Streptozoc | 02 | N | PLATO TRIAL | 100365462 |
| 20041273 | 20086173 | 1.77 | 59.6 | 03 | 2018-10-17 | 2018-10-31 | Capecitabine+Cisplatin+Streptozocin | 02 | N | NAB-PACLITAXEL | 101214194 |